Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 250 of 348 entries
View as:

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02383212 Org: User:
Start: 02/02/15 End: 11/18/19 Due: 11/18/20

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Phase: N/A Priority: Normal
NCT ID: NCT03682770 Org: User:
Start: 10/03/18 End: 07/23/21 Due: 07/23/22

Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01893528 Org: User:
Start: 06/30/13 End: 09/30/14 Due: 09/30/15

A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)

Phase: N/A Priority: Normal
NCT ID: NCT05088460 Org: User:
Start: 02/28/22 End: 04/18/24 Due: 04/18/25

Study of REGN3500 and Dupilumab in Patients With Asthma

Phase: N/A Priority: Normal
NCT ID: NCT03112577 Org: User:
Start: 06/15/17 End: 12/09/19 Due: 12/09/20

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

Phase: N/A Priority: Normal
NCT ID: NCT06491914 Org: User:
Start: 07/24/24 End: 01/07/27 Due: 01/07/28

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Phase: N/A Priority: Normal
NCT ID: NCT00943072 Org: User:
Start: 07/31/09 End: 04/30/12 Due: 04/30/13

A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05481333 Org: User:
Start: 10/24/22 End: 08/29/23 Due: 08/29/24

Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans

Phase: N/A Priority: Normal
NCT ID: NCT04506645 Org: User:
Start: 09/01/20 End: 12/14/22 Due: 12/14/23

Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02121080 Org: User:
Start: 05/31/14 End: 02/28/15 Due: 02/28/16

Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03233139 Org: User:
Start: 06/21/17 End: 09/30/27 Due: 09/30/28

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT03738423 Org: User:
Start: 11/13/18 End: 07/24/20 Due: 07/24/21

Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

Phase: N/A Priority: Normal
NCT ID: NCT04159415 Org: User:
Start: 01/07/20 End: 09/24/24 Due: 09/24/25

A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable

Phase: N/A Priority: Normal
NCT ID: NCT02755649 Org: User:
Start: 01/31/16 End: 03/31/17 Due: 03/31/18

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

Phase: N/A Priority: Normal
NCT ID: NCT01730040 Org: User:
Start: 10/31/12 End: 05/31/14 Due: 05/31/15

Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares

Phase: N/A Priority: Normal
NCT ID: NCT00610363 Org: User:
Start: 11/30/07 End: 10/31/08 Due: 10/31/09

Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03492489 Org: User:
Start: - End: - Due: -

Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01209793 Org: User:
Start: 11/30/10 End: 09/30/11 Due: 09/30/12

Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain

Phase: N/A Priority: Normal
NCT ID: NCT01001923 Org: User:
Start: 12/31/09 End: 01/31/11 Due: 01/31/12

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

Phase: N/A Priority: Normal
NCT ID: NCT00509795 Org: User:
Start: 08/31/07 End: 07/31/11 Due: 07/31/12

Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT01548404 Org: User:
Start: 04/30/12 End: 06/30/13 Due: 06/30/14

A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

Phase: N/A Priority: Normal
NCT ID: NCT05169489 Org: User:
Start: 01/24/22 End: 08/31/25 Due: 08/31/26

PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)

Phase: N/A Priority: Normal
NCT ID: NCT00958438 Org: User:
Start: 07/31/09 End: 12/31/10 Due: 12/31/11

A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00794417 Org: User:
Start: 11/30/08 End: 06/30/11 Due: 06/30/12

VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00045266 Org: User:
Start: 04/30/02 End: - Due: -